Loading...
OTCM
CVSI
Market cap6mUSD
Jul 31, Last price  
0.04USD
1D
-9.32%
1Q
33.33%
Jan 2017
-91.63%
IPO
-99.29%
Name

CV Sciences Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.93
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.40%
Rev. gr., 5y
-33.15%
Revenues
7m
-55.21%
002,154,06310,190,66711,529,40211,060,63620,679,23948,244,00053,696,00024,429,00020,048,00016,205,00016,004,0007,168,000
Net income
-2m
L
-90,180-45,611-2,300,196-1,311,951-12,233,128-14,141,298-4,897,13910,001,000-16,610,000-22,284,000-15,554,000-8,214,0003,102,000-2,394,000
CFO
-861k
L
-79,632-64,084-4,879,234-6,711,999-4,208,267-2,053,7403,615,00412,559,000-2,138,000-7,300,000-7,485,000-1,885,0002,253,000-861,000
Earnings
Aug 11, 2025

Profile

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
URL
https://cvsciences.com/
IPO date
Oct 04, 2018
Employees
42
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,168
-55.21%
16,004
-1.24%
16,205
-19.17%
Cost of revenue
9,358
18,564
23,052
Unusual Expense (Income)
NOPBT
(2,190)
(2,560)
(6,847)
NOPBT Margin
Operating Taxes
(8)
(6)
(47)
Tax Rate
NOPAT
(2,182)
(2,554)
(6,800)
Net income
(2,394)
-177.18%
3,102
-137.76%
(8,214)
-47.19%
Dividends
Dividend yield
Proceeds from repurchase of equity
554
BB yield
-12.39%
Debt
Debt current
83
384
1,340
Long-term debt
102
246
493
Deferred revenue
(11)
Other long-term liabilities
19
124
11
Net debt
(269)
(687)
19,134
Cash flow
Cash from operating activities
(861)
2,253
(1,885)
CAPEX
(18)
Cash from investing activities
(28)
(156)
Cash from financing activities
32
(1,391)
1,121
FCF
(2,414)
(3,094)
(5,089)
Balance
Cash
454
1,317
611
Long term investments
(17,912)
Excess cash
96
517
Stockholders' equity
(86,978)
(84,561)
(87,674)
Invested Capital
88,875
87,040
81,731
ROIC
ROCE
115.42%
EV
Common stock shares outstanding
175,585
153,955
138,034
Price
0.03
-4.38%
0.04
9.10%
0.03
-72.21%
Market cap
5,935
9.05%
5,442
21.69%
4,472
-64.42%
EV
5,666
4,755
23,606
EBITDA
(1,734)
(2,325)
(5,855)
EV/EBITDA
Interest
1,541
Interest/NOPBT